Medical Condition News

RSS

FDA advises consumers, health care professionals about Xenical, Alli

The U.S. Food and Drug Administration today advised consumers and health care professionals about potential rare occurrences of severe liver injury in patients taking the weight-loss medication orlistat, marketed as Xenical and Alli.

27 May 2010

New study holds promise for patients with LCA

A new study led by Dr. Robert Koenekoop at the Montreal Children's Hospital at the McGill University Health Centre holds promise for certain patients with Leber congenital amaurosis, an inherited retinal degenerative disease that causes significant vision loss from birth. The study, sponsored by Canadian company QLT Inc., is designed to treat patients with LCA due to genetic mutations in either retinal pigment epithelium protein 65 or lecithin:retinol acyltransferase.

27 May 2010

Increased BMI levels not attributed to sugar consumption: Study

A new independent study of scientific research has revealed that, contrary to the widely held hypothesis, dietary sugars are not the driving factor behind rising body mass index (BMI) levels in children in Great Britain.

27 May 2010

Nottingham scientists given green light to test new vaccine for malignant melanoma

Nottingham scientists have been given the green light to test a vaccine which they hope could reverse, and even cure malignant melanoma, the most deadly type of skin cancer.

27 May 2010

Health Canada approves Victoza for treatment of adults with type 2 diabetes

Diabetes is growing at an alarming rate in Canada, with an estimated 3.7 million people expected to be diagnosed by 2020. It is a progressive disease that, if not properly monitored and managed over time, will lead to serious long term complications. Canadians now have a novel treatment available to help them maintain optimal blood glucose levels. Health Canada has approved Victoza (liraglutide), the first GLP-1 analogue, for once-daily administration for the treatment of adults with type 2 diabetes to improve glycemic control in combination with metformin or metformin and a sulfonylurea.

27 May 2010

Drug and dosage influence risk of GI bleeding

A study conducted at the Spanish Centre for Pharmacoepidemiological Research revealed that the risk of gastrointestinal complications due to nonsteroidal anti-inflammatory drug (NSAID) use varies by specific NSAID administered and by dosage. The study further determined that NSAIDs with a long half-life or slow-release formulation are associated with a greater risk of GI bleeding or perforation.

27 May 2010

Researchers use new imaging technique to view microvessels in the brains of living mice

Researchers at Northwestern University Feinberg School of Medicine have identified in mice a previously unknown protective mechanism by which the smallest blood vessels remove blood clots and other blockages from the brain. The findings provide insights into mechanisms that may be involved in age-related cognitive decline, Alzheimer's disease and recovery from stroke.

27 May 2010

GSK Consumer Healthcare announces update of alli product label

GSK Consumer Healthcare today announced it will update the alli product label to alert consumers to certain symptoms that have been associated with rare instances of severe liver injury reported in people taking orlistat, the active ingredient in alli. This update follows FDA's completion of its safety review of orlistat and is being implemented in conjunction with Roche, the manufacturer of the prescription dose of orlistat (Xenical). The agency stated that a cause and effect relationship has not been established.

27 May 2010

PBI awarded contract to provide essential laboratory data for Phase I cardiovascular trial

Pacific Biomarkers, Inc. has been awarded a contract by a leading multinational pharmaceutical company to provide essential laboratory data for an adaptive Phase I cardiovascular trial. This study is part of a major drug-development program to evaluate an innovative new treatment to reduce recurrent cardiovascular events associated with acute coronary syndrome.

27 May 2010

Rates of cardiovascular disease increase in Australian winters: Seasonal researcher

Rates of cardiovascular disease increase dramatically in Australian winters because many people don't know how to rug up against the cold, a Queensland University of Technology seasonal researcher has found.

27 May 2010

Bacteria may play wider role in people predisposed to obesity: Researchers

Bacteria may play more of a role in people predisposed to obesity than previously thought, according to studies presented today by University of Maryland School of Medicine researchers at the 110th general meeting of the American Society for Microbiology in San Diego.

27 May 2010

FDA accepts Horizon Pharma's DUEXA NDA for review

Horizon Pharma, Inc., a late-stage biopharmaceutical company focused on the development and commercialization of innovative medicines for pain-related diseases and inflammation, today announced that its New Drug Application (NDA) for DUEXA®, a proprietary tablet formulation containing a fixed-dose combination of ibuprofen and high-dose famotidine, was accepted by the U.S. Food and Drug Administration (FDA) for review.

27 May 2010

Abbott's TREK Coronary Dilatation Catheter receives European approval

Abbott today announced the European approval and launch of its TREK™ Coronary Dilatation Catheter for the treatment of coronary artery disease. The TREK system represents a new approach to balloon catheter design, and provides physicians with a high-performing option for treating challenging lesions and difficult-to-reach blockages. Abbott received CE Mark for the TREK system earlier this year.

26 May 2010

Cardiovascular Systems initiates enrollment in ORBIT II IDE clinical trial of Diamondback 360 System

Cardiovascular Systems, Inc., announces the first patient enrollment in its ORBIT II Investigational Device Exemption (IDE) clinical trial to evaluate the safety and effectiveness of its Diamondback 360® System in treating coronary arteries. The patient was treated by Dr. P.K. Khanna, an interventional cardiologist with Eisenhower Medical Center in Palm Springs, Calif. Dr. Khanna also treated patients in the 2008 ORBIT I coronary study of 50 patients in India.

26 May 2010

Investment banker with Brachial Plexus Palsy climbs all Seven Summits

Paul Fejtek has successfully achieved his goal of being the first person with Brachial Plexus Palsy to climb all Seven Summits (the highest mountain on each continent). With wife Denise by his side, Paul reached the earth's highest peak and paused for a moment to take it all in. "Standing on the summit of Mt. Everest was truly amazing," he said. "It was the experience of a lifetime."

26 May 2010

Lymphoma Foundation Canada applauds Ontario government's decision to publicly fund Rituxan for CLL

Lymphoma Foundation Canada (LFC) applauds Ontario's recent decision to publicly fund Rituxan (rituximab) in combination with Fludarabine-based chemotherapy for patients with previously untreated chronic lymphocytic leukemia (CLL).

26 May 2010

Research findings offer possible applications in diagnosis and treatment of patients with atherosclerosis

Researchers from Boston University School of Medicine have shown that use of magnetic resonance imaging in an animal model can non-invasively identify dangerous plaques. The findings, which appear in the May issue of Circulation Cardiovascular Imaging, offer possible applications in the diagnosis and treatment of patients with atherosclerosis.

26 May 2010

St. Jude Medical to evaluate cost-effectiveness of FFR for multivessel coronary artery disease

St. Jude Medical, Inc., a global medical device company, announced today at EuroPCR it will evaluate the incremental cost-effectiveness of Fractional Flow Reserve (FFR)-guided treatment for patients with multivessel coronary artery disease in the UK, Germany, France, Italy, Switzerland, Belgium and Canada. The analysis will also determine FFR's potential health and budget impact for each of the seven countries.

26 May 2010

CTRC starts enrolment in Phase 2 combination trial of REOLYSIN and gemcitabine for advanced pancreatic cancer

Oncolytics Biotech Inc. announced today that the Cancer Therapy & Research Center at the University of Texas Health Science Center in San Antonio (CTRC) has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with gemcitabine (Gemzar(R)) in patients with advanced pancreatic cancer. The Principal Investigator is Dr. Monica Mita of the CTRC.

26 May 2010

National Council on Skin Cancer Prevention introduces Don't Fry Day to encourage sun safety awareness

As millions of Americans prepare to enjoy the great outdoors Memorial Day weekend, the National Council on Skin Cancer Prevention reminds everyone to practice sun-safe behaviors – pack those wide-brimmed hats in the suitcase. The incidence of melanoma (the most fatal of skin cancers) continues to rise significantly, at a rate faster than any of the seven most common cancers.

26 May 2010

Medical Condition News

FDA advises consumers, health care professionals about Xenical, Alli

New study holds promise for patients with LCA

Increased BMI levels not attributed to sugar consumption: Study

Nottingham scientists given green light to test new vaccine for malignant melanoma

Health Canada approves Victoza for treatment of adults with type 2 diabetes

Drug and dosage influence risk of GI bleeding

Researchers use new imaging technique to view microvessels in the brains of living mice

GSK Consumer Healthcare announces update of alli product label

PBI awarded contract to provide essential laboratory data for Phase I cardiovascular trial

Rates of cardiovascular disease increase in Australian winters: Seasonal researcher

Bacteria may play wider role in people predisposed to obesity: Researchers

FDA accepts Horizon Pharma's DUEXA NDA for review

Abbott's TREK Coronary Dilatation Catheter receives European approval

Cardiovascular Systems initiates enrollment in ORBIT II IDE clinical trial of Diamondback 360 System

Investment banker with Brachial Plexus Palsy climbs all Seven Summits

Lymphoma Foundation Canada applauds Ontario government's decision to publicly fund Rituxan for CLL

Research findings offer possible applications in diagnosis and treatment of patients with atherosclerosis

St. Jude Medical to evaluate cost-effectiveness of FFR for multivessel coronary artery disease

CTRC starts enrolment in Phase 2 combination trial of REOLYSIN and gemcitabine for advanced pancreatic cancer

National Council on Skin Cancer Prevention introduces Don't Fry Day to encourage sun safety awareness

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Latest News